BridgeBio Pharma Shares Are Trading Higher After the Company Announced That the FDA Approved Attruby to Treat Adults With ATTR-CM. Also, HC Wainwright Maintained a Buy Rating on the Stock and Raised Its Price Target From $43 to $49.
BridgeBio Pharma Shares Are Trading Higher After the Company Announced That the FDA Approved Attruby to Treat Adults With ATTR-CM. Also, HC Wainwright Maintained a Buy Rating on the Stock and Raised Its Price Target From $43 to $49.
bridgebio pharma的股票在公司宣佈FDA批准Attruby用於治療成人ATTR-Cm後上漲。此外，HC Wainwright維持了對該股票的買入評級，並將其目標價格從43美元提高到49美元。
BridgeBio Pharma Shares Are Trading Higher After the Company Announced That the FDA Approved Attruby to Treat Adults With ATTR-CM. Also, HC Wainwright Maintained a Buy Rating on the Stock and Raised Its Price Target From $43 to $49.
bridgebio pharma的股票在公司宣佈FDA批准Attruby用於治療成人ATTR-Cm後上漲。此外，HC Wainwright維持了對該股票的買入評級，並將其目標價格從43美元提高到49美元。
熱門討論
FOMC維持利率但不確定性高企：美股後市走向如何？
🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？
Moo Live
03/20 02:25
聯邦公開市場委員會新聞發佈會，2025年3月19日